Physician profile
Ryan James Katides
NPI 1093315863
$6,436.27
in general payments reported to CMS, 2019-2025
26 companies · $4,717 in 2025
The $4,717 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $251 · 2023: $1,031 · 2024: $437 · 2025: $4,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,563 · Food and Beverage: $1,397 · Consulting Fee: $750 · Education: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,563.00 |
| Food and Beverage | $1,397.40 |
| Consulting Fee | $750.00 |
| Education | $474.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $3,687.46 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $794.70 | 2023-2025 | Lynparza |
| Astellas Pharma US INC | $627.98 | 2023-2025 | Xtandi |
| Seagen INC. | $309.92 | 2022-2023 | Padcev, Adcetris |
| Janssen Biotech, INC. | $160.38 | 2022-2025 | Erleada, Tecvayli, Talvey |
| Mirati Therapeutics, INC. | $118.95 | 2023 | Krazati |
| Amgen INC. | $99.74 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $88.40 | 2023-2025 | Opdivo, Augtyro |
| Foundation Medicine, INC. | $66.73 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.27 | 2023-2024 | Fruzaqla, Entyvio, Hyqvia |
| Sanofi-Aventis U.S. LLC | $44.19 | 2023 | |
| Celgene Corporation | $40.39 | 2023-2024 | Reblozyl |
| Karyopharm Therapeutics INC. | $36.79 | 2023 | Xpovio |
| Abbvie INC. | $35.86 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $34.05 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.69 | 2023-2024 | Keytruda, Lynparza |
| Cti Biopharma Corp. | $24.96 | 2023 | Vonjo |
| Aveo Pharmaceuticals, INC. | $24.87 | 2024 | |
| Caris Mpi, INC. | $24.54 | 2025 | Mi Cancer Seek |
| Beone Medicines USA, INC. | $23.05 | 2025 | Brukinsa |
| Exelixis INC. | $22.45 | 2023 | Cabometyx |
| Gilead Sciences, INC. | $21.48 | 2023 | |
| Lilly USA, LLC | $19.61 | 2025 | |
| Novocure INC. | $18.00 | 2025 | |
| Eisai INC. | $17.07 | 2024 | |
| Incyte Corporation | $12.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Katides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.